ECOG OPERATIONS OFFICE

ECOG 运营办公室

• 批准号: 3556595
• 负责人: DOUGLASS C TORMEY
• 金额: $ 209.76万
• 依托单位: AMC CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-01 至 1994-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556595
• 关键词: DNA replication; Epstein Barr virus; acute leukemia; breast neoplasm /cancer diagnosis; breast neoplasms; cancer information system; carmustine; combination cancer therapy; combination chemotherapy; computer assisted diagnosis; cooperative study; cytogenetics; drug adverse effect; endocrine neoplasm; epidermal growth factor; estrogen receptors; flow cytometry; gene expression; head /neck neoplasm; histopathology; human subject; human therapy evaluation; immunocytochemistry; in situ hybridization; kidney neoplasms; lung neoplasms; lymphadenectomy; melanoma; metastasis; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer genetics; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer thermotherapy; oncogenes; prognosis; radiation therapy dosage; surface antigens

The overall goal of the ECOG Operations Office is to provide leadership and support for multi disciplinary clinical trials designed to improve cancer therapy. To achieve this the specific aims are as follows: A. Improving clinical trials efficiency by diminishing lag times in protocol development, forms development, and protocol review; developing (computer) on-line randomization access and checklists; and eliminating unnecessary requirements for registration, on study requirements and follow up measurements. B. Initiating new scientific thrusts by incorporating into our clinical trials elements of modern cancer biology, including biologic response modifier agents, growth factors, immunochemistry, molecular probes for oncogenes, and cytogenetics. C. Providing resources to our MOC and DOC chairs to support protocol development, to initiate implementation of laboratory projects, to monitor the conduct of trials, and to plan for new studies. D. Enhancing the accrual of patients into major protocols such as the NCI high priority initiatives, Phase 3 trials and Genitourinary cancers by providing administrative and fiscal support to enlist patients from new or established participants.

ECOG 运营办公室的总体目标是提供 多学科临床试验的领导和支持 旨在改善癌症治疗。 为实现这一目标，具体 目标如下： A. 通过减少滞后时间提高临床试验效率 协议开发、表格开发和协议审查； 开发（计算机）在线随机化访问和检查表； 并消除不必要的注册要求，学习 要求和后续测量。 B. 通过将我们的研究纳入其中，发起新的科学推动力 现代癌症生物学的临床试验要素，包括 生物反应调节剂、生长因子、免疫化学、 癌基因和细胞遗传学的分子探针。 C. 向我们的 MOC 和 DOC 主席提供资源以支持 制定协议，启动实验室实施 项目，监督试验的进行，并规划新的 研究。 D. 增加患者参与主要方案的机会，例如 NCI 高优先级计划、第 3 阶段试验和泌尿生殖系统 通过提供行政和财政支持来防治癌症 来自新的或已建立的参与者的患者。